Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179978 | 1.00 | P2RX7 (0.57) | P2RX7TSHRCYP2C19CYP3A4MEN1 | |
| SCHEMBL311394 | 0.90 | P2RX7 (0.58) | P2RX7TSHRCYP2C19CYP3A4MEN1 | |
| SCHEMBL1190522 | 0.90 | P2RX7 (0.58) | P2RX7TSHRCYP2C19CYP3A4MEN1 | |
| SCHEMBL1005866 | 0.90 | P2RX7 (0.58) | P2RX7TSHRCYP2C19CYP3A4MEN1 | |
| SCHEMBL3333492 | 0.87 | P2RX7 (0.56) | P2RX7CYP2C19MEN1KMT2AEHMT2 | |
| SCHEMBL10215490 | 0.87 | P2RX7 (0.56) | P2RX7MEN1KMT2AEHMT2HCRTR1 | |
| SCHEMBL10270030 | 0.85 | P2RX7 (0.57) | P2RX7CYP3A4MEN1KMT2AHCRTR1 | |
| SCHEMBL3337871 | 0.85 | P2RX7 (0.57) | P2RX7CYP3A4MEN1KMT2AHCRTR1 | |
| SCHEMBL1189916 | 0.84 | P2RX7 (0.53) | P2RX7TSHRCYP2C19MEN1KMT2A | |
| SCHEMBL2907566 | 0.84 | P2RX7 (0.53) | P2RX7TSHRCYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943160-B2 | Morpholine derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM PLC (GB) | 2005-09-13 | — | — | US | disclosed |
| EP-1353918-B1 | MORPHOLINE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2005-01-12 | — | — | EP | disclosed |
| US-20040058921-A1 | Morpholine derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM PLC (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1353918-A1 | MORPHOLINE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002044172-A1 | MORPHOLINE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058921-A1 | Morpholine derivatives as antagonists of orexin receptors | HCRTR2, HCRTR1, OXTR | P2RX7 317/4885TSHR 191/4885CYP2C19 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.